公开(公告)号：US20230312723A1

公开(公告)日：2023-10-05

申请号：US18050236

申请日：2022-10-27

Applicant: Genentech, Inc.

Inventor： Mark Lawrence MCCLELAND ,  Simonetta MOCCI ,  Wei ZOU ,  Yu DENG ,  Hiroshi KURIKI

IPC: C07K16/28 ,  C12Q1/6886 ,  G01N33/574 ,  A61K31/519 ,  A61K33/243 ,  A61K31/282 ,  A61P35/00

CPC classification number: C07K16/2827 ,  C12Q1/6886 ,  G01N33/57492 ,  A61K31/519 ,  A61K33/243 ,  A61K31/282 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70596 ,  C07K2317/24

Abstract: The disclosure provides methods and compositions for treating non-small cell lung cancer (NSCLC; e.g., squamous or non-squamous NSCLC, including stage IV NSCLC) in a subject, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) in combination with a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine) to the subject. Exemplary subjects that may be treated using the compositions and methods of the disclosure include those that exhibits a heightened blood tumor mutational burden (bTMB) score relative to a reference bTMB score. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab) and/or a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating NSCLC (e.g., squamous or non-squamous NSCLC, including stage IV NSCLC) in a subject, such as a subject having an elevated bTMB score prior to the onset of treatment.

公开(公告)号：US20220412981A1

公开(公告)日：2022-12-29

申请号：US17686565

申请日：2022-03-04

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： David FABRIZIO ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Marcin KOWANETZ ,  David SHAMES ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY ,  Wei ZOU

IPC: G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US20200157635A1

公开(公告)日：2020-05-21

申请号：US16591813

申请日：2019-10-03

Applicant: Genentech, Inc.

Inventor： Marcin KOWANETZ ,  Mahrukh HUSENI ,  Wei ZOU

IPC: C12Q1/6886 ,  G01N33/50 ,  C07K16/28

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).